Cargando…

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats

Tofacitinib, a Janus kinase inhibitor, was developed for the treatment of rheumatoid arthritis. Recently, it has been associated with an increased change in arthritis development in patients with diabetes. Herein, we evaluated the pharmacokinetics of tofacitinib after intravenous (10 mg/kg) and oral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gwak, Eun Hye, Yoo, Hee Young, Kim, So Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327145/ https://www.ncbi.nlm.nih.gov/pubmed/32209733 http://dx.doi.org/10.4062/biomolther.2020.006

Ejemplares similares

Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
por: Bae, Sung Hun, et al.
Publicado: (2022)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib
por: Kim, Sa Rang, et al.
Publicado: (2018)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases
por: Sanachai, Kamonpan, et al.
Publicado: (2020)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
por: Won, Jong Mun, et al.
Publicado: (2023)

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
por: Gaber, Timo, et al.
Publicado: (2020)

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
por: Hall, Stephen, et al.
Publicado: (2018)

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
por: Zhang, Junmei, et al.
Publicado: (2023)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
por: Aleisa, Ahmad I., et al.
Publicado: (2020)

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
por: Hasni, Sarfaraz A., et al.
Publicado: (2021)

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Various Application of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
por: Sadeghi, Sara, et al.
Publicado: (2022)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report
por: Komeda, Yoriaki, et al.
Publicado: (2020)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis
por: Talty, Ronan, et al.
Publicado: (2021)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report
por: Li, Ben, et al.
Publicado: (2020)

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
por: Lichtenstein, Gary R, et al.
Publicado: (2020)

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with N-Dimethylnitrosamine-Induced Liver Cirrhosis
por: Bae, Sung Hun, et al.
Publicado: (2022)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
por: Shivanna, Chandrashekar Byalekere, et al.
Publicado: (2018)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
por: Lee, Ji Sang, et al.
Publicado: (2019)

Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
por: Koh, Jung Hee, et al.
Publicado: (2023)

Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion
por: Bae, Sung Hun, et al.
Publicado: (2020)

Idiopathic erythema multiforme: Evidence of underlying Janus kinase–signal transducer and activator of transcription activation and successful treatment with tofacitinib
por: Damsky, William, et al.
Publicado: (2016)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sc582n6qpr5cpjt9ot10f5mm7b